First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence

被引：3
|
作者：
Hafner, Susanne [1 ]
机构：
[1] Ulm Univ, Inst Pharmacol Nat Prod & Clin Pharmacol, D-89081 Ulm, Germany
来源：
SIGNAL TRANSDUCTION AND TARGETED THERAPY | 2021年 / 6卷 / 01期
关键词：
CELL LUNG-CANCER; BEVACIZUMAB; ERLOTINIB; MULTICENTER;
D O I：
10.1038/s41392-021-00813-y
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [1] First-line anti-VEGF plus EGFR-TKI in EGFR-mutant NSCLC: adding the ARTEMIS trial to the puzzle of current evidence
    Susanne Hafner
    Signal Transduction and Targeted Therapy, 6
  • [2] First-Line Continual EGFR-TKI Plus LAT Demonstrated Survival Benefit in Egfr-Mutant Nsclc Patients with Oligoprogressive Disease
    Xu, Q.
    Liu, H.
    Hang, T.
    Ren, S.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S592 - S592
  • [3] First-line continual EGFR-TKI plus local ablative therapy demonstrated survival benefit in EGFR-mutant NSCLC patients with oligoprogressive disease
    Xu, Qinghua
    Liu, Hui
    Meng, Shuyan
    Jiang, Tao
    Li, Xuefei
    Liang, Shixiong
    Ren, Shengxiang
    Zhou, Caicun
    JOURNAL OF CANCER, 2019, 10 (02): : 522 - 529
  • [4] First-line treatment in NSCLC harboring EGFR common mutations: EGFR TKI in monotherapy or in combination with anti-VEGF?
    Passaro, Antonio
    Spitaleri, Gianluca
    de Marinis, Filippo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (08) : 799 - 801
  • [5] Factors affecting PS deterioration at the time of relapse after the first-line EGFR-TKI therapy in EGFR-mutant advanced NSCLC
    Tamura, Tomoki
    Hotta, Katsuyuki
    Gotoda, Hiroko
    Kato, Yuka
    Ichihara, Eiki
    Kubo, Toshio
    Tanimoto, Mltsune
    Kiura, Katsuyuki
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [6] Effect of smoking habits on the efficacy of EGFR-TKI plus anti-angiogenic agent in advanced EGFR-mutant NSCLC
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Yan
    Wu, Ying
    Ling, Yan
    Liu, Ke
    Zang, Yuan-Sheng
    LUNG CANCER, 2022, 170 : 91 - 97
  • [7] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
    Huang, Y. H.
    Hsu, K. -H.
    Tseng, J. -S.
    Chen, K. -C.
    Chang, G. -C.
    Yang, T. -Y.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
  • [8] Efficacy of EGFR-TKI Plus Chemotherapy or Monotherapy as First-Line Treatment for Advanced EGFR-Mutant Lung Adenocarcinoma Patients With Co-Mutations
    Yang, Zhengyu
    Chen, Ya
    Wang, Yanan
    Wang, Shuyuan
    Hu, Minjuan
    Zhang, Bo
    Han, Baohui
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [9] First-line concomitant EGFR-TKI plus chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials
    Landre, Thierry
    Assie, Jean-Baptiste
    Chouahnia, Kader
    Des Guetz, Gaetan
    Auliac, Jean-Bernard
    Chouaid, Christos
    EXPERT REVIEW OF ANTICANCER THERAPY, 2024, 24 (08) : 775 - 780
  • [10] Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC
    Fiala, O.
    Pesek, M.
    Finek, J.
    Benesova, L.
    Bortlicek, Z.
    Minarik, M.
    NEOPLASMA, 2013, 60 (04) : 425 - 431
12345